Adaptam Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$11.7M
- Investors
-
3
Adaptam Therapeutics General Information
Description
Developer of antibody-based therapies designed to overcome the immunosuppressive myeloid tumor microenvironment in cancer. The company offers targeted biologics against novel immune checkpoints, enabling oncology researchers and clinicians to advance more effective immunotherapies for hard-to-treat tumors.
Contact Information
Website
www.adaptamtx.comCorporate Office
- Gipuzkoa Science and Technology Park Tandem Building
- Paseo Miramón 170
- 20014 Donostia-San Sebastian
- Spain
Corporate Office
- Gipuzkoa Science and Technology Park Tandem Building
- Paseo Miramón 170
- 20014 Donostia-San Sebastian
- Spain
Adaptam Therapeutics Timeline
Adaptam Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC | 22-Oct-2025 | $11.7M | Completed | Startup | ||
| 3. Early Stage VC | 27-Oct-2025 | Completed | Startup | |||
| 2. Accelerator/Incubator | 01-Jan-2021 | $5K | $5K | Completed | Startup | |
| 1. Spin-Off | Completed | Startup |
Adaptam Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Adaptam Therapeutics Patents
Adaptam Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260022170-A1 | Anti-siglec-9 antibodies and uses thereof | Pending | 10-May-2024 | ||
| WO-2025233867-A1 | Anti-siglec-9 antibodies and uses thereof | Pending | 10-May-2024 | ||
| US-20250361297-A1 | Anti- siglec-15 binding molecules and methods of use | Pending | 12-Mar-2024 | ||
| AU-2025237727-A1 | Anti-siglec-15 antibodies and uses thereof | Pending | 12-Mar-2024 | ||
| WO-2025191498-A1 | Anti-siglec-15 antibodies and uses thereof | Pending | 12-Mar-2024 | C07K16/2803 |
Adaptam Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Adaptam Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Caixa Capital Risc | Corporate Venture Capital | Minority | ||
| Criteria Bio Ventures | Venture Capital | Minority | ||
| Ekin + Program | Accelerator/Incubator |
Adaptam Therapeutics FAQs
-
When was Adaptam Therapeutics founded?
Adaptam Therapeutics was founded in 2021.
-
Where is Adaptam Therapeutics headquartered?
Adaptam Therapeutics is headquartered in Donostia-San Sebastian, Spain.
-
What is the size of Adaptam Therapeutics?
Adaptam Therapeutics has 4 total employees.
-
What industry is Adaptam Therapeutics in?
Adaptam Therapeutics’s primary industry is Drug Discovery.
-
Is Adaptam Therapeutics a private or public company?
Adaptam Therapeutics is a Private company.
-
What is Adaptam Therapeutics’s current revenue?
The current revenue for Adaptam Therapeutics is .
-
How much funding has Adaptam Therapeutics raised over time?
Adaptam Therapeutics has raised $15.2M.
-
Who are Adaptam Therapeutics’s investors?
Caixa Capital Risc, Criteria Bio Ventures, and Ekin + Program have invested in Adaptam Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
